TTNT for systemic therapies delivered across all treatment lines
| Systemic therapy groups . | N = 721 lines of systemic therapy . | Median line of therapy (IQR) . | Median TTNT (months) (95% CI) . | % free from next line of treatment at 1 year (95% CI) . | % free from next line of treatment at 2 years (95% CI) . |
|---|---|---|---|---|---|
| Monotherapies | |||||
| Biological monotherapy | 10 | 8 (4-11) | — | — | — |
| Extracorporeal photopheresis (ECP) monotherapy | 47 | 2 (1-4) | 5.2 (4.1-7.6) | 14.2 (5.8-26.3) | 11.4 (4.0-23.1) |
| Histone deacetylase (HDAC) inhibitor monotherapy | 43 | 5 (3-8) | 60 (3.3-7.9) | 12.8 (4.7-25.0) | 6.4 (1.3-17.7) |
| Immunosuppressant monotherapy | 1 | — | — | — | — |
| Interferon monotherapy | 46 | 2 (1-3) | 5.0 (4.0-7.4) | 18.5 (8.7-31.1) | 11.5 (4.2-22.9) |
| Methotrexate monotherapy | 47 | 1 (1-3) | 5.0 (3.3-6.5) | 29.3 (16.8-43.0) | 19.5 (9.3-32.5) |
| Monoclonal antibody–based monotherapy | 99 | 4 (3-6) | 8.7 (6.2-11.6) | 36.3 (26.2-46.5) | 20.4 (11.5-31.2) |
| Retinoid monotherapy | 73 | 2 (1-3) | 6.0 (4.2-8.5) | 31.2 (20.8-42.2) | 13.2 (6.3-22.6) |
| Systemic chemotherapy, multiagent monotherapy∗ | 57 | 5 (3-7) | 3.1 (2.8-3.8) | 1.9 (0.2-8.9) | 0 |
| Systemic chemotherapy, single-agent monotherapy | 100 | 4 (2-5) | 4.3 (3.2-5.0) | 6.9 (2.8-13.3) | 1.1 (0.1-5.5) |
| Stem cell transplant, allogeneic | 24 | 4 (3-5.5) | — | 80.1 (55.2-92.1) | 72.1 (44.0-87.8) |
| Stem cell transplant, autologous | 1 | — | — | — | — |
| Combination therapies | |||||
| ECP–based combination therapy | 142 | 2 (1-3) | 6.7 (5.4-8.4) | 28.2 (20.9-35.9) | 10.9 (6.2-17.1) |
| Interferon–based combination therapy | 14 | 3 (1-5) | 2.5 (1.5-9.2) | 21.4 (5.2-44.8) | 21.4 (5.2-44.8) |
| Other combinations of systemic therapies | 17 | 6 (4-8) | 2.1 (1.2-4.0) | 9.5% (0.8-32.2) | 0 |
| Systemic therapy groups . | N = 721 lines of systemic therapy . | Median line of therapy (IQR) . | Median TTNT (months) (95% CI) . | % free from next line of treatment at 1 year (95% CI) . | % free from next line of treatment at 2 years (95% CI) . |
|---|---|---|---|---|---|
| Monotherapies | |||||
| Biological monotherapy | 10 | 8 (4-11) | — | — | — |
| Extracorporeal photopheresis (ECP) monotherapy | 47 | 2 (1-4) | 5.2 (4.1-7.6) | 14.2 (5.8-26.3) | 11.4 (4.0-23.1) |
| Histone deacetylase (HDAC) inhibitor monotherapy | 43 | 5 (3-8) | 60 (3.3-7.9) | 12.8 (4.7-25.0) | 6.4 (1.3-17.7) |
| Immunosuppressant monotherapy | 1 | — | — | — | — |
| Interferon monotherapy | 46 | 2 (1-3) | 5.0 (4.0-7.4) | 18.5 (8.7-31.1) | 11.5 (4.2-22.9) |
| Methotrexate monotherapy | 47 | 1 (1-3) | 5.0 (3.3-6.5) | 29.3 (16.8-43.0) | 19.5 (9.3-32.5) |
| Monoclonal antibody–based monotherapy | 99 | 4 (3-6) | 8.7 (6.2-11.6) | 36.3 (26.2-46.5) | 20.4 (11.5-31.2) |
| Retinoid monotherapy | 73 | 2 (1-3) | 6.0 (4.2-8.5) | 31.2 (20.8-42.2) | 13.2 (6.3-22.6) |
| Systemic chemotherapy, multiagent monotherapy∗ | 57 | 5 (3-7) | 3.1 (2.8-3.8) | 1.9 (0.2-8.9) | 0 |
| Systemic chemotherapy, single-agent monotherapy | 100 | 4 (2-5) | 4.3 (3.2-5.0) | 6.9 (2.8-13.3) | 1.1 (0.1-5.5) |
| Stem cell transplant, allogeneic | 24 | 4 (3-5.5) | — | 80.1 (55.2-92.1) | 72.1 (44.0-87.8) |
| Stem cell transplant, autologous | 1 | — | — | — | — |
| Combination therapies | |||||
| ECP–based combination therapy | 142 | 2 (1-3) | 6.7 (5.4-8.4) | 28.2 (20.9-35.9) | 10.9 (6.2-17.1) |
| Interferon–based combination therapy | 14 | 3 (1-5) | 2.5 (1.5-9.2) | 21.4 (5.2-44.8) | 21.4 (5.2-44.8) |
| Other combinations of systemic therapies | 17 | 6 (4-8) | 2.1 (1.2-4.0) | 9.5% (0.8-32.2) | 0 |
Excluding low dose methotrexate monotherapy